Inside Two Real Drug Programs: A Decade of Talking to the FDA

Drug development is mostly invisible to the rest of us. Here's what it actually looks like when a small company and the FDA work the same hard problem for years — told straight from the original letters, meeting minutes, and submissions, purchased and donated to the Commons so anyone can learn from how the work really happened.

On method. This is one sponsor's story, read from its own files — both programs were sponsored by Allena (ALLN-177 / reloxaliase, which began at Altus as ALTU-237, and ALLN-346). It's a close look at how a single company's decade with the FDA actually unfolded, not a representative sample of how drug development goes. Nothing here is regulatory or legal advice.

The two programs

Reloxaliase — an oral enzyme that breaks down oxalate in the gut (oxalate overload drives kidney stones and kidney damage). The IND was approved in 2007; the conversation started even earlier, with a 2006 pre-IND meeting.
ALLN-346 — an oral enzyme that breaks down uric acid, for gout in patients with advanced kidney disease. The IND was submitted at the end of 2019.

By the numbers

~140 submission sequences filed to the FDA for Reloxaliase over its life (~50 for the younger ALLN-346).
~16 years of back-and-forth with the FDA for Reloxaliase, beginning with that 2006 pre-IND meeting.
55 and 59 days — how long the FDA took to decide two "special status" requests (ALLN-346's Fast Track, granted; Reloxaliase's Breakthrough Therapy, denied). The legal deadline is 60.
~2,500 documents across the two dossiers — the eCTD paper trail, now open for anyone to read.

The story worth telling: "No, no, no… yes."

Reloxaliase's whole journey turned on a single question: can a drug be approved by showing it lowers oxalate in the urine — without waiting years to prove it actually prevents kidney stones?

The FDA said no at the pivotal End-of-Phase-2 meeting (2017), and no again at the next meeting (2018), each time asking for a model connecting that lab number to real-world stones. The company kept coming back with new analyses. In December 2018, the FDA finally agreed to a faster "accelerated approval" path — but only if the company could show both a large enough effect and a credible link to real patient benefit. Getting from "no" to "yes" took about three years.

Tasty morsels & lessons

A lab number isn't a finish line. "Biologically plausible" isn't enough — regulators want a quantitative bridge from your measurement to a real outcome patients feel.
The FDA is remarkably consistent. It repeated the same concern across years and even quoted its own past letters. The lesson: read the old minutes before every meeting.
"Serious disease" opens the door; evidence walks through it. Reloxaliase's Breakthrough Therapy request was denied — the FDA agreed the disease was serious, but found the early data (just seven patients, several on dialysis, which itself removes oxalate) too thin. ALLN-346's Fast Track request, by contrast, was granted quickly.
Making the drug is its own saga. The manufacturing process was rebuilt four times as the program scaled up (FFDB → Lonza → intermediate → full scale).
Persistence is a strategy. Endpoints get rejected and designations get denied — and good programs keep going by bringing better data to the next meeting.

Want the FDA's exact words, and what each phrase really means? Read the companion field guide, Reading Between the Lines.

These records were purchased and donated to the Commons. Explore the full timeline and the original FDA letters yourself — create a free account to browse the Reloxaliase and ALLN-346 dossiers across Modules 1–5.